Classen Immunotherapies, Inc. Company Profile

18:59 EDT 20th June 2018 | BioPortfolio

Tel: 410-377-8526

News Articles [184 Associated News Articles listed on BioPortfolio]

Infographic: Discovering The Current Landscape of Immunotherapies

Together with the experts at Theravectys, we have created an absolutely amazing Infographic full of cool and fun facts about Immunotherapies. Click on the image below to download the complete Infogra...

STAT Plus: A new way of testing tumors may help match patients with cancer immunotherapies

There's an emerging new tool that might clear up the fog around immunotherapies — if its predictive promise can be confirmed in large clinical trials.

New Genetic Sequence Data Map May Lead to New Immunotherapies

ImmunoMap, which can examine t-cell receptor repertoire relatedness, may help predict clinical outcome for patients with cancer and could be a new tool for designing vaccines and immunotherapies.

Turning up the heat on resistant tumours with novel immunotherapies

A promising class of drugs known as CD40 monoclonal antibodies could be the spark needed to light the fire in the immune system of patients who don't respond to the newer cancer immunotherapies. Robe...

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After ra...

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH (Reuters) - The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they...

Molecular 'magnets' could help develop better immunotherapies for cancer patients

Chemicals that attract specialized immune cells toward tumors could be used to develop better immunotherapies for cancer patients, according to new research published in Cell.

Two immunotherapies used together for the first time to tackle tumors

(Medical College of Georgia at Augusta University) Two immunotherapies -- one that enables the T-cells a patient already has to better attack a tumor and another that can produce an independent and vi...

Drugs and Medications [0 Results]


PubMed Articles [69 Associated PubMed Articles listed on BioPortfolio]

Next generation immunotherapies for lymphoma: one foot in the future.

Improved understanding of the interactions between cancer cells and the immune system combined with technological advances has led to the development of novel types of immunotherapies. These include c...

Animal Models for Studying Tumor Microenvironment (TME) and Resistance to Lymphocytic Infiltration.

In cancer immunotherapy, cytotoxic T or NK cells need to engage cancer cells to initiate the killing. However, in clinical studies and in mouse models, some solid tumors are found with no lymphocytes....

Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: a histologic and immunohistochemistry analysis.

The advent of targeted therapies using BRAF or MEK inhibitors (BRAFi or MEKi) or their combinations (BiMiC) as well as checkpoint immunotherapies based on antibodies to CTLA4 or PD1 has recently broug...

Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer.

The therapeutic armamentarium for advanced non-small-cell lung cancer has evolved considerably over the past years. Immune checkpoint inhibitors targeting programmed cell death-1 such as pembrolizumab...

Immunoengineering with biomaterials for enhanced cancer immunotherapy.

Cancer immunotherapy has recently shown dramatic clinical success inducing durable response in patients of a wide variety of malignancies. Further improvement of the clinical outcome with immune relat...

Clinical Trials [27 Associated Clinical Trials listed on BioPortfolio]

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other ...

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Recent scientific advances have shown the important role of immune system against cancer. Today, many immunological biotherapy like anti-PD1/PDL-1 are available in cancer treatment and gen...

GI-4000 With Adoptive Transfer in Pancreatic Cancer

The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be complete...

Prospective Tissue Collection Research Protocol

This study aims to collect matched donor tissue and blood to enable the development of a manufacturing process for potential immunotherapies.

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The combination of GSK1795091 and GSK3174998 will be evalu...

Companies [50 Associated Companies listed on BioPortfolio]

Classen Immunotherapies, Inc.

Tel: 410-377-8526

CTL ImmunoTherapies

CTL ImmunoTherapies, located in Chatsworth, California, is a biotechnology company focusing on the discovery, development and manufacturing of theraputic vaccines.

Advaxis, Inc. and Rodman & Renshaw, LLC

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform tech...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...


OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fu...

More Information about "Classen Immunotherapies, Inc." on BioPortfolio

We have published hundreds of Classen Immunotherapies, Inc. news stories on BioPortfolio along with dozens of Classen Immunotherapies, Inc. Clinical Trials and PubMed Articles about Classen Immunotherapies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Classen Immunotherapies, Inc. Companies in our database. You can also find out about relevant Classen Immunotherapies, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record